Tumor Shrinkage Archives

Lilly’s targeted RET drug shrinks tumors in lung cancer trial

Acquisitions, Advanced lung cancer, Business, Clinical Trials, European Society for Medical Oncology (ESMO), FDA, Gene Abnormalities, Liver Enzymes, Non-Small Cell Lung Cancer, Papillary Thyroid Cancer, R&D, RET Gene, Tumor Shrinkage, Tumors, World Conference on Lung Cancer

Eli Lilly and Co.’s LOXO-292, an experimental cancer drug the company acquired in January 2019 as part of an $8 billion takeover of Loxo Oncology, shrank tumors in nearly 70 percent of advanced lung cancer patients whose tumors carried specific abnormalities in the RET gene.

Amgen drug shrinks lung cancer tumors in half of patients: study

Advanced lung cancer, Cancer Cells, Cancer Deaths, Checkpoint Inhibitors, Chemotherapy, Clinical Data, Clinical Trials, Colorectal Cancer, Genetic Mutations, Immune System, KRAS Mutations, Non-Small Cell Lung Cancer, R&D, Tumor Shrinkage, Wall Street, World Conference on Lung Cancer

An experimental Amgen Inc. drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial.

Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study

Advanced bladder cancer, Chemotherapy, Clinical Data, Immunotherapies, Tumor Shrinkage

An experimental drug developed by Seattle Genetics Inc. and Astellas Pharma Inc. led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to presented data.